SEC For	rm 4 FORM	4 U	NITE		FES :	SF	ECU	RITIE	S AN	ID F	XCHAN	IGE		OMMI	SSIOI	N			
				TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB APPROVAL					
Check this box if no longer subject STATEMEN			о ти	T OF CHANGES IN BENEFICIAL OWNERSHIP										OMB Number: 3235-0287 Estimated average burden					
U obligat	tion 16. Form 4 tions may conti tion 1(b).			Filed	l pursua or Se	ant ecti	to Sec on 30(tion 16(a h) of the) of the S Investme	Securit ent Co	ies Exchang mpany Act of	e Act f 1940	of 193)	34				response:	0.5
	nd Address of	f Reporting Person [*] SLP/IL						e and Tio 1erape			Symbol [RPTX]				lationship ck all app Direc	licable)	•	erson(s) to I X 10% C	
(Last) (First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year) 11/02/2023							7	Officer (give title Other (specify below) below)								
44 MONTGOMERY STREET 40TH FLOOR			4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Ind Line)										
(Street)														x	Form	filed by Mo		porting Pers an One Rep	
SAN FRANC	ISCO CA	A 9	4104		Ru	le	10b	5-1(c)) Tran	sac	tion Indi	cati	on						
(City)	(St	ate) (J	Zip)			Che sati:	eck this sfy the	box to inc affirmative	icate that defense	a tran: conditi	saction was ma ons of Rule 10	ade pi)b5-1(ırsuani c). See	t to a cont Instructio	tract, instru on 10.	uction or writ	ten pl	an that is inte	ended to
		Table	I - No	n-Deriva	tive s	Se	curit	ies Ac	quired	, Dis	posed of	, or	Bene	eficiall	y Own	ed			
1. Title of Security (Instr. 3) 2. Trai Date				saction I/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)			es Acquired (A) or Df (D) (Instr. 3, 4 a					For (D)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
						ľ	montai	Duyrrea	Code	v	Amount	(A (D) or)	Price	- Report Transa				(Instr. 4)
Common	Common Shares, no par value ⁽¹⁾		11/02/	2023	T			Р	\square	218,979		A	\$ <mark>3.6</mark>	4,6	62,402		D ⁽²⁾		
Common Shares, no par value ⁽¹⁾ 11/02/2			2023	123		Р		492,251		A \$3.6		3,792,157			D ⁽³⁾				
Common Shares, no par value ⁽¹⁾ 11/02/2			2023	/23		Р		72,479		A	\$ <mark>3.6</mark>	48	485,083		D ⁽⁴⁾				
		Ta									osed of, o convertib				Owned	d			
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any		4. Transaction Code (Instr. 8)		on o str. D A (/ D (I	n of		Exerc tion Da /Day/\		And 7. Title and Amount of Securities Underlying Derivative Security (Ir 3 and 4)		De Se I	Price of erivative ecurity istr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	y Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownershi (Instr. 4)	
					Code	v		A) (D)	Date Exercis	sable	Expiration Date	Title	or Nun of	ount nber res					
	nd Address of	Reporting Person*																	
,		(First)	() 41	ddle)		-													
(Last) 44 MON 40TH FI		Y STREET	(ivin	uie)															
(Street) SAN FRANC	ISCO	CA	94	104		_													
(City)		(State)	(Zip)		-													
		f Reporting Person [*] OGY VALUI		ID L P															
(Last) 44 MON 40TH FI	TGOMER	(First) Y STREET	(Mio	ddle)		_													
(Street) SAN FRANC	ISCO	CA	94	104		_													

1. Name and Address of Reporting Person^{*}

(State)

(Zip)

(City)

(Last)	(First)	(Middle)
44 MONTGOM	IERY STREET	
40TH FLOOR		
(Street)		
SAN	CA	94104
FRANCISCO	CA	34104
(City)	(State)	(Zip)
1. Name and Addre	ess of Reporting Person [*]	
BIOTECHN	OLOGY VALUE	<u>FUND II LP</u>
(Last)	(First)	(Middle)
44 MONTGOM	. ,	(
40TH FLOOR		
(Otura at)		
(Street) SAN		
FRANCISCO	CA	94104
(City)	(State)	(Zip)
,		(קיב)
1. Name and Addre <u>BVF II GP L</u>	ess of Reporting Person [*] . <u>LC</u>	
,		
(Last)	(First)	(Middle)
44 MONTGOM	IERY STREET	
40TH FLOOR		
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
	oc of Doporting Doroon*	
1. Name and Addre	ess of Reporting Person	
	<u>gy Value Trading I</u>	Fund OS LP
Biotechnolog	<u>gy Value Trading I</u>	
Biotechnolog (Last)	<u>gy Value Trading I</u> (First)	Fund OS LP (Middle)
Biotechnolog (Last)	<u>gy Value Trading I</u>	
Biotechnolog (Last)	<u>gy Value Trading I</u> (First)	
Biotechnolog (Last) P.O. BOX 309 T (Street) GRAND	<u>gy Value Trading I</u> (First)	
Biotechnolog (Last) P.O. BOX 309 T (Street)	<u>gy Value Trading I</u> (First) JGLAND HOUSE	(Middle)
Biotechnolog (Last) P.O. BOX 309 T (Street) GRAND	<u>gy Value Trading I</u> (First) JGLAND HOUSE	(Middle)
Biotechnolog (Last) P.O. BOX 309 T (Street) GRAND CAYMAN (City)	<u>(First)</u> JGLAND HOUSE E9	(Middle) KY1-1104
Biotechnolog (Last) P.O. BOX 309 T (Street) GRAND CAYMAN (City)	(First) JGLAND HOUSE E9 (State)	(Middle) KY1-1104
Biotechnolog (Last) P.O. BOX 309 T (Street) GRAND CAYMAN (City) 1. Name and Addree	(First) JGLAND HOUSE E9 (State)	(Middle) KY1-1104
Biotechnolog (Last) P.O. BOX 309 T (Street) GRAND CAYMAN (City) 1. Name and Addree BVF Partner (Last)	(First) JGLAND HOUSE E9 (State) ess of Reporting Person* s OS Ltd. (First)	(Middle) KY1-1104
Biotechnolog (Last) P.O. BOX 309 T (Street) GRAND CAYMAN (City) 1. Name and Addree BVF Partner (Last)	(First) JGLAND HOUSE E9 (State) ess of Reporting Person* s OS Ltd.	(Middle) KY1-1104 (Zip)
Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addre BVF Partner (Last) P.O. BOX 309 U	(First) JGLAND HOUSE E9 (State) ess of Reporting Person* s OS Ltd. (First)	(Middle) KY1-1104 (Zip)
Biotechnolog (Last) P.O. BOX 309 T (Street) GRAND CAYMAN (City) 1. Name and Addree BVF Partner (Last)	(First) JGLAND HOUSE E9 (State) ess of Reporting Person* s OS Ltd. (First) JGLAND HOUSE	(Middle) KY1-1104 (Zip) (Middle)
Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addre BVF Partner (Last) P.O. BOX 309 U (Street)	(First) JGLAND HOUSE E9 (State) ess of Reporting Person* s OS Ltd. (First)	(Middle) KY1-1104 (Zip)
Biotechnolog (Last) P.O. BOX 309 T (Street) GRAND CAYMAN (City) 1. Name and Addre BVF Partner (Last) P.O. BOX 309 T (Street) GRAND CAYMAN	y Value Trading I (First) JGLAND HOUSE E9 (State) ess of Reporting Person* s OS Ltd. (First) JGLAND HOUSE E9	(Middle) KY1-1104 (Zip) (Middle) KY1-1104
Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addre BVF Partner (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City)	y Value Trading I (First) JGLAND HOUSE E9 (State) ess of Reporting Person* s OS Ltd. (First) JGLAND HOUSE E9 (State)	(Middle) KY1-1104 (Zip) (Middle)
Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addre BVF Partner (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addre	y Value Trading I (First) JGLAND HOUSE E9 (State) ess of Reporting Person* s OS Ltd. (First) JGLAND HOUSE E9	(Middle) KY1-1104 (Zip) (Middle) KY1-1104
Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addre BVF Partner (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addre	y Value Trading I (First) JGLAND HOUSE E9 (State) ess of Reporting Person* s OS Ltd. (First) JGLAND HOUSE E9 (State) ess of Reporting Person*	(Middle) KY1-1104 (Zip) (Middle) KY1-1104
Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addree BVF Partner (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addree BVF GP HO (Last)	y Value Trading I (First) JGLAND HOUSE E9 (State) ess of Reporting Person* s OS Ltd. (First) JGLAND HOUSE E9 (State) ess of Reporting Person* LDINGS LLC (First)	(Middle) KY1-1104 (Zip) (Middle) KY1-1104
Biotechnolog (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addre BVF Partner (Last) P.O. BOX 309 U (Street) GRAND CAYMAN (City) 1. Name and Addre BVF GP HO	y Value Trading I (First) JGLAND HOUSE E9 (State) ess of Reporting Person* s OS Ltd. (First) JGLAND HOUSE E9 (State) ess of Reporting Person* LDINGS LLC (First)	(Middle) KY1-1104 (Zip) (Middle) KY1-1104 (Zip)

SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
1. Name and Address <u>BVF INC/IL</u>	of Reporting Person [*]	
(Last) 44 MONTGOMEH 40TH FLOOR	(First) RY STREET	(Middle)
(Street) SAN FRANCISCO	СА	94104
(City)	(State)	(Zip)
1. Name and Address		
(Last) 44 MONTGOMER 40TH FLOOR (Street)	(First) RY STREET	(Middle)
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)

Explanation of Responses:

1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively beneficially owns over 10% of the Issuer's outstanding Common Shares. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially the own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser beneficially own the securities owned directly by Trading Fund OS. As the deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

<u>BVF Partners L.P., By: BVF</u> <u>Inc., its general partner, By: /s/</u> <u>11/03/2023</u> <u>Mark N. Lampert, President</u>
Biotechnology Value Fund,L.P., By: BVF I GP LLC, itsgeneral partner, By: /s/ Mark11/03/2023N. Lampert, Chief ExecutiveOfficer
BVF I GP LLC, By: /s/ MarkN. Lampert, Chief Executive11/03/2023Officer
Biotechnology Value Fund II,L.P., By: BVF II GP LLC, itsgeneral partner, By: /s/ Mark11/03/2023N. Lampert, Chief ExecutiveOfficer
BVF II GP LLC, By: /s/ MarkN. Lampert, Chief Executive11/03/2023Officer11/03/2023
Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
BVF Partners OS Ltd., By: 11/03/2023 BVF Partners L.P., its sole 11/03/2023 member, By: BVF Inc., its 11/03/2023

general partner, By: /s/ Mark
N. Lampert, PresidentItemBVF GP Holdings LLC, By:
/s/ Mark N. Lampert, Chief
Executive Officer11/03/2023BVF Inc., By: /s/ Mark N.
Lampert, President11/03/2023/s/ Mark N. Lampert11/03/2023** Signature of Reporting PersonDate

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.